The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system—including psychiatric drugs—are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.

Table of Contents


Front Matter
Introduction
1 Perspectives from the FDA, Academia, and Patients
2 Data Collection and Optimization
3 Data Analysis
4 Partnerships, Opportunities, Collaboration
Appendix A: References
Appendix B: Workshop Agenda
Appendix C: Workshop Attendees
Appendix D: Biographical Sketches of Invited Speakers